Nabriva Therapeutics (NASDAQ:NBRV) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Nabriva Therapeutics (NASDAQ:NBRVFree Report) in a research report sent to investors on Tuesday morning. The firm issued a hold rating on the biotechnology company’s stock.

Nabriva Therapeutics Price Performance

The company has a current ratio of 0.85, a quick ratio of 0.52 and a debt-to-equity ratio of 0.12. Nabriva Therapeutics has a fifty-two week low of $1.22 and a fifty-two week high of $8.45. The company has a market capitalization of $45.46 million, a price-to-earnings ratio of -0.07 and a beta of 1.53.

About Nabriva Therapeutics

(Get Free Report)

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration.

See Also

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.